MAPK Pathway Mutations Emerge in Mutant IDH1 Inhibitor–Resistant Cholangiocarcinoma and Attenuate the IFN ResponseJinkai Wan(Massachusetts General Hospital), N. Bardeesy(Massachusetts General Hospital)Clinical Cancer ResearchDecember 29, 202510.1158/1078-0432.ccr-25-3284Cited by 1SaveCiteExport RISWatch citationsRelated PapersDNAJB1-PRKACA Fusion Drives Fibrolamellar Liver Cancer through Impaired SIK Signaling and CRTC2/p300-Mediated Transcriptional Reprogramming|Cancer Discovery|2024|14Generation of a Biliary Tract Cancer Cell Line Atlas Identifies Molecular Subtypes and Therapeutic Targets|Cancer Discovery|2025|11Data from DNAJB1-PRKACA Fusion Drives Fibrolamellar Liver Cancer through Impaired SIK Signaling and CRTC2/p300-Mediated Transcriptional Reprogramming|Unknown|2025|3Contents of Supplementary Tables from DNAJB1-PRKACA Fusion Drives Fibrolamellar Liver Cancer through Impaired SIK Signaling and CRTC2/p300-Mediated Transcriptional Reprogramming|Unknown|2025|0Supplementary Tables S1-S7 from DNAJB1-PRKACA Fusion Drives Fibrolamellar Liver Cancer through Impaired SIK Signaling and CRTC2/p300-Mediated Transcriptional Reprogramming|Unknown|2025|0